Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat autoimmune and inflammatory diseases caused by immune system imbalances. By utilizing proprietary platform technologies, the company aims to induce durable immune tolerance, providing a potential cure for patients suffering from these conditions.
Funding
$365.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
RFounders
Product
Problem
Autoimmune and inflammatory diseases arise from imbalances in the immune system, leading to the body attacking its own tissues. Current treatments often manage symptoms but do not provide a durable cure, leaving patients with chronic conditions and potential side effects from long-term immunosuppression.
Solution
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies designed to restore immune balance and provide lasting remission for autoimmune and inflammatory diseases. The company's approach involves engineering and administering Tregs, a specialized type of immune cell responsible for suppressing excessive immune responses and maintaining immune tolerance. By harnessing the power of Tregs, Sonoma Bio aims to re-establish equilibrium in the immune system, addressing the underlying cause of autoimmune disorders rather than just managing symptoms. Their platform aims to create targeted and potent Treg therapies that can precisely modulate the immune response in specific tissues or organs affected by autoimmune disease.
Target Audience
The primary target audience includes patients suffering from autoimmune and inflammatory diseases, as well as physicians specializing in rheumatology, gastroenterology, dermatology, and other fields related to autoimmune disorders.
Features
- Engineered Treg cell therapies designed to target and suppress specific autoimmune responses
- Proprietary platform technologies for Treg engineering, expansion, and characterization
- Focus on restoring immune balance rather than broad immunosuppression
- Development of therapies for various autoimmune and inflammatory diseases
- Clinical trials underway to evaluate the safety and efficacy of Treg therapies
- Manufacturing capabilities for producing high-quality cell therapies